查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553557

乳癌治療市場規模、佔有率、趨勢分析報告：按治療、最終用途、地區和細分市場預測，2024-2030 年

Breast Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By End Use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

乳癌治療市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球乳癌治療市場規模將達到428.7億美元，2024年至2030年複合年成長率為9.1%。

這種成長主要是由治療技術的進步、乳癌盛行率的增加以及對個人化醫療的日益關注所推動的。根據美國乳癌基金會的數據，美國八分之一的女性在一生中會被診斷出罹患乳癌。到 2024 年，估計將有 310,720 名女性和 2,800 名男性被診斷出患有侵襲性乳癌。在最早的局部階段診斷出的乳癌的五年相對存活率為 99%。近年來，早期檢測和治療的進步顯著提高了存活率，目前美國有超過 400 萬名乳癌倖存者。

乳癌是乳癌的一種常見形式，目前正在透過多種創新療法來治療，包括標標靶治療、免疫療法和荷爾蒙療法。市場規模的擴大歸因於新藥和新治療方法的不斷開拓，提高了治療效果並改善了患者預後。此外，人們對乳癌的認知不斷提高，以及早期檢測的重要性也促使對先進治療方案的需求不斷成長。

全球乳癌負擔日益增加，加上人口老化和發病率上升，也推動了市場擴張。隨著越來越多的患者尋求先進的治療方法以及醫療保健系統對最尖端科技的投資，乳癌治療市場預計將顯著成長。精準醫學的技術進步，例如基因組分析和生物標記識別，正在實現更個人化的治療方法。這些創新使癌細胞能夠更有效地被靶向，同時最大限度地減少副作用，並改善整體患者體驗。此外，正在進行的研究和臨床試驗可能會引入新的治療方法和聯合治療，這可能會進一步推動市場成長。

乳癌治療市場報告亮點

  • 2023年，標靶治療領域佔最大佔有率，達27.6%。這一優勢反映了向更精確、更有效的治療方法的轉變，並凸顯了標靶治療在乳癌治療中的變革性影響。
  • 醫院板塊佔比最大，2023年將超過60.0%。這種成長主要是由於乳癌的高盛行率，推動了對醫院治療的巨大需求。
  • 市場上的一些知名企業包括默克公司、百時美施貴寶公司、協和麒麟公司、衛材公司、賽諾菲公司、輝瑞公司、Astra Zeneca、諾華公司、禮來公司和羅氏公司。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章乳癌治療市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 乳癌治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19 的影響

第4章全球乳癌治療市場：依治療分類的估計與趨勢分析

  • 全球乳癌治療市場：治療儀表板
  • 全球乳癌治療市場：治療變異分析
  • 全球乳癌治療市場（按治療方式）
  • 化療
  • 標靶治療
  • 荷爾蒙療法
  • 免疫療法
  • 放射治療
  • 其他

第5章乳癌治療市場：依最終用途分類的估計與趨勢分析

  • 全球乳癌治療市場：最終用途儀表板
  • 全球乳癌治療市場：最終用途變化分析
  • 全球乳癌治療市場（按最終用途）
  • 醫院
  • 專科診所
  • 其他

第6章乳癌治療市場：按地區、治療、最終用途進行估計和趨勢分析。

  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業熱圖分析
  • 公司簡介
    • Merck &Co
    • Bristol Myers Squiib
    • Kyowa Kirin
    • Eisai Co.Ltd
    • Sanofi
    • Pfizer Inc
    • AstraZeneca
    • Novartis AG
    • Eli Lilly and Company
    • F. Hoffmann La Roche AG
Product Code: GVR-4-68040-425-7

Breast Adenocarcinoma Treatment Market Growth & Trends:

The global breast adenocarcinoma treatment market size is expected to reach USD 42.87 billion by 2030 and is projected to grow at a CAGR of 9.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. This growth is significantly driven by the advancements in treatment technologies, the increasing prevalence of breast adenocarcinoma, and a growing focus on personalized medicine. According to the National Breast Cancer Foundation, in the U.S., 1 in 8 women will be diagnosed with breast cancer during their lifetime. For 2024, an estimated 310,720 women and 2,800 men are expected to be diagnosed with invasive breast cancer. The 5-year relative survival rate for breast cancer diagnosed at its earliest, localized stage is 99%. Advances in early detection and treatment have markedly improved survival rates in recent years, resulting in over 4 million breast cancer survivors currently living in the U.S.

Breast adenocarcinoma, a common form of breast cancer, is being addressed through a range of innovative treatments that include targeted therapies, immunotherapies, and hormonal therapies. The rise in market size can be attributed to the continual development of new drugs and therapies that enhance treatment efficacy and improve patient outcomes. In addition, the increasing awareness of breast cancer and the importance of early detection are contributing to a higher demand for advanced treatment options.

The increasing global burden of breast cancer, coupled with an aging population and rising incidence rates, is also fueling market expansion. As more patients seek advanced treatment options and healthcare systems invest in cutting-edge technologies, the market for breast adenocarcinoma treatments is set to grow significantly. Technological advancements in precision medicine, such as genomic profiling and biomarker identification, are enabling more personalized treatment approaches. These innovations allow for more effective targeting of cancer cells while minimizing side effects, thus enhancing the overall patient experience. Furthermore, ongoing research and clinical trials are likely to introduce novel therapies and combination treatments that could further drive market growth.

Breast Adenocarcinoma Treatment Market Report Highlights:

  • The targeted therapy segment held the largest share of 27.6 % in 2023. This prominence underscores the transformative impact of targeted therapies on breast cancer treatment, reflecting a shift towards more precise and effective treatment modalities.
  • The hospitals segment held the largest share of more than 60.0% in 2023. This growth is largely due to the high prevalence of breast cancer, which drives significant demand for hospital-based treatments.
  • Some of the prominent players in market are Merck & Co; Bristol Myers Squibb; Kyowa Kirin; Eisai Co. Ltd; Sanofi; Pfizer Inc; AstraZeneca; Novartis AG; Eli Lilly and Company; F. Hoffmann La Roche AG

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Treatment
    • 1.1.2. End Use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
    • 1.6.3. Volume price analysis (Model 2)
    • 1.6.4. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. End Use Outlook
    • 2.2.3. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Breast Adenocarcinoma Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Prevalence of Breast Cancer
      • 3.2.1.2. Advancements In Treatment Modalities
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Stringent Regulation And Approvals
      • 3.2.2.2. High Cost of Treatments
  • 3.3. Breast Adenocarcinoma Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. COVID-19 Impact

Chapter 4. Global Breast Adenocarcinoma Treatment Market: Treatment Estimates & Trend Analysis

  • 4.1. Global Breast Adenocarcinoma Treatment Market: Treatment Dashboard
  • 4.2. Global Breast Adenocarcinoma Treatment Market: Treatment Movement Analysis
  • 4.3. Global Breast Adenocarcinoma Treatment Market, Treatment
  • 4.4. Chemotherapy
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
  • 4.5. Targeted Therapy
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
  • 4.6. Hormonal Therapy
    • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)
  • 4.7. Immunotherapy
    • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Billion)
  • 4.8. Radiation Therapy
    • 4.8.1. Market estimates and forecast 2018 to 2030 (USD Billion)
  • 4.9. Other
    • 4.9.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 5. Breast Adenocarcinoma Treatment Market: End Use Estimates & Trend Analysis

  • 5.1. Global Breast Adenocarcinoma Treatment Market: End Use Dashboard
  • 5.2. Global Breast Adenocarcinoma Treatment Market: End Use Movement Analysis
  • 5.3. Global Breast Adenocarcinoma Treatment Market, End Use
  • 5.4. Hospitals
    • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
  • 5.5. Specialty Clinics
    • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 6. Breast Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis, By Treatment, and By End Use.

  • 6.1. Regional Market Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.6. Singapore
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments and Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company heat map analysis, 2023
  • 7.4. Company Profiles
    • 7.4.1. Merck & Co
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Bristol Myers Squiib
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Kyowa Kirin
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Eisai Co.Ltd
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Sanofi
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Pfizer Inc
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. AstraZeneca
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Novartis AG
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Eli Lilly and Company
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. F. Hoffmann La Roche AG
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 3 North America Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 4 North America Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 5 U.S. Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 6 U.S. Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 7 Canada Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 8 Canada Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 9 Europe Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 10 Europe Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 11 Europe Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 12 Germany Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 13 Germany Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 14 UK Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 15 UK Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 16 France Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 17 France Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 18 Italy Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 19 Italy Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 20 Spain Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 21 Spain Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 22 Denmark Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 23 Denmark Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 24 Sweden Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 25 Sweden Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 26 Norway Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 27 Norway Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 28 Asia Pacific Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 29 Asia Pacific Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 30 Asia Pacific Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 31 China Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 32 China Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 33 Japan Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 34 Japan Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 35 India Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 36 India Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 37 South Korea Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 38 South Korea Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 39 South Korea Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 40 Australia Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 41 Australia Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 42 Thailand Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 43 Thailand Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 44 Latin America Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 45 Latin America Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 46 Latin America Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 47 Brazil Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 48 Brazil Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 49 Mexico Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 50 Mexico Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 51 Argentina Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 52 Argentina Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 53 MEA Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 54 MEA Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 55 MEA Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 56 South Africa Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 57 South Africa Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 58 Saudi Arabia Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 59 Saudi Arabia Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 60 UAE Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 61 UAE Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 62 Kuwait Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 63 Kuwait Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 64 Kuwait Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Breast Adenocarcinoma Treatment Market: Market Outlook
  • Fig. 9 Breast Adenocarcinoma Treatment Competitive Insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Breast Adenocarcinoma Treatment Market Driver Impact
  • Fig. 15 Breast Adenocarcinoma Treatment Market Restraint Impact
  • Fig. 16 Breast Adenocarcinoma Treatment Market Strategic Initiatives Analysis
  • Fig. 17 Breast Adenocarcinoma Treatment Market: Treatment Movement Analysis
  • Fig. 18 Breast Adenocarcinoma Treatment Market: Treatment Outlook And Key Takeaways
  • Fig. 19 Chemotherapy market estimates and forecast, 2018 - 2030
  • Fig. 20 Targeted therapy market estimates and forecast, 2018 - 2030
  • Fig. 21 Hormonal therapy market estimates and forecast, 2018 - 2030
  • Fig. 22 Immunotherapy market estimates and forecast, 2018 - 2030
  • Fig. 23 Radiation therapy market estimates and forecast, 2018 - 2030
  • Fig. 24 Other market estimates and forecast, 2018 - 2030
  • Fig. 25 Breast Adenocarcinoma Treatment Market: End Use Movement Analysis
  • Fig. 26 Breast Adenocarcinoma Treatment Market: End Use Outlook And Key Takeaways
  • Fig. 27 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 28 Specialty clinics market estimates and forecast, 2018 - 2030
  • Fig. 29 Global Breast Adenocarcinoma Treatment Market: Regional Movement Analysis
  • Fig. 30 Global Breast Adenocarcinoma Treatment Market: Regional Outlook And Key Takeaways
  • Fig. 31 Global Breast Adenocarcinoma Treatment market share and leading companies
  • Fig. 32 North America: SWOT
  • Fig. 33 Europe SWOT
  • Fig. 34 Asia Pacific SWOT
  • Fig. 35 Latin America SWOT
  • Fig. 36 MEA SWOT
  • Fig. 37 North America, by country
  • Fig. 38 North America
  • Fig. 39 North America market estimates and forecasts, 2018 - 2030
  • Fig. 40 U.S.
  • Fig. 41 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 42 Canada
  • Fig. 43 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 44 Mexico
  • Fig. 45 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 46 Europe
  • Fig. 47 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 48 UK
  • Fig. 49 UK market estimates and forecasts, 2018 - 2030
  • Fig. 50 Germany
  • Fig. 51 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 52 France
  • Fig. 53 France market estimates and forecasts, 2018 - 2030
  • Fig. 54 Italy
  • Fig. 55 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 56 Spain
  • Fig. 57 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 58 Denmark
  • Fig. 59 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 60 Sweden
  • Fig. 61 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 62 Norway
  • Fig. 63 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 64 Asia Pacific
  • Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 66 China
  • Fig. 67 China market estimates and forecasts, 2018 - 2030
  • Fig. 68 Japan
  • Fig. 69 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 70 India
  • Fig. 71 India market estimates and forecasts, 2018 - 2030
  • Fig. 72 Singapore
  • Fig. 73 Singapore market estimates and forecasts, 2018 - 2030
  • Fig. 74 South Korea
  • Fig. 75 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 76 Australia
  • Fig. 77 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 78 Latin America
  • Fig. 79 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 80 Brazil
  • Fig. 81 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 82 Argentina
  • Fig. 83 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 84 Middle East and Africa
  • Fig. 85 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 86 South Africa
  • Fig. 87 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 88 Saudi Arabia
  • Fig. 89 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 90 UAE
  • Fig. 91 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 92 Kuwait
  • Fig. 93 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 94 Market share of key market companies - Breast Adenocarcinoma Treatment market